OncoSec Medical Inc (NASDAQ:ONCS) issued positive updated long-term follow-up report from its Phase II OMS I-102 combination trial of pembrolizumab and ImmunoPulse® IL-12 in patients doubtful to respond to anti-PD-1 treatment.
The updated report will be showcased in an oral poster presentation by Dr. Alain Alagzi at the SITC Annual Meeting on November 10, 2017. The event will comprise a discussion and presentation of updated clinical report for the firm’s ImmunoPulse IL-12 program, showcasing the international, registration-directed PISCES/KEYNOTE-695 study.
The updated correlative and clinical immune-focused biomarker data exhibited a 57% progression free survival rate at 15 months with 100% duration of response and median progression free survival not yet reached. Building upon earlier issued report of a best overall response rate of 50%, the updated data further show that the combination of these treatments can prime a coordinated adaptive and innate immune response, and firmly indicates a synergistic association with anti-PD-1.
The latest data further show that this combination plan can reshape the tumor microenvironment, resulting in a systemic anti-tumor and robust intratumoral response converting “cold” tumors to “hot,” probably improving clinical results in patients expected to not respond to anti-PD-1 treatment.
Dr. Alain Algazi, the Lead Trial Investigator, expressed that overall, the Phase II study data, counting progression free survival beyond 2 years in numerous patients, best overall response rate, tolerability of the combination and duration of response, offer a consistent and strong theme across numerous endpoints, underlining the promise of pembrolizumab and ImmunoPulse IL-12 as a viable treatment alternative for people diagnosed with metastatic melanoma.
Dan O’Connor, the CEO of OncoSec, expressed that the impressive PFS tolerability and benefit seen with ImmunoPulse IL-12 and pembrolizumab is the initial demonstrating efficacy in a foreseen PD-1 non-responder population and demonstrates that the combination exhibits a potentially vital addition to the treatment setting for people with metastatic melanoma who are progressing or have progressed on anti-PD-1 therapy.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: